ArticleBiochemistry and biophysics reports2025
Oenological tannins mitigate rotenone-induced mitochondrial impairments and oxidative stress, with concomitant detection of urolithin A in the brain.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondria are key organelles that supply energy to the brain, and their dysfunction contributes to neurotoxicity induced by environmental toxins such as rotenone. Recently, oenological tannins (OTs) and their colonic metabolite, urolithin A (UA), have been emphasized due to their potential neuroprotective activity. However, their role in counteracting toxin-induced mitochondrial impairments remains unclear. Therefore, this study aimed to investigate the administration of OTs to rotenone (ROT)-induced mitochondrial dysfunction and oxidative stress, key contributors to neurotoxicity. We measured mitochondrial membrane potential (MMP), the activity of mitochondrial complex I (Grishchuk et al.), and aldehyde dehydrogenase 2 (ALDH2) to assess mitochondria and protein carbonyl (PC) levels. We also checked the presence of UA in the brain. Our results indicate that the OTs treatment restored MMP, increased MCI and ALDH2 activity, and decreased PC content in ROT-induced rats. Furthermore, we confirmed the presence of UA in the brains of the animals. While its exact contribution to the observed mitochondrial effects remains undetermined, this finding suggests a potential role of the gut-derived metabolite in neuroprotection. Thus, we conclude that OTs administration attenuates mitochondria-related neurotoxicity. We call for further mechanistic studies and the putative contribution of metabolites, including UA, to the demonstrated mitoprotective effect of OTs treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.